Choroba zakrzepowo-zalorowa w przebiegu choroby nowotworowej

Abstract

Author(s): Biedka Marta, Makarewicz Adrianna, Makarewicz Roman, Ziólkowska Ewa

Venous thromboembolism (VTE) contributes to morbidity and mortality in cancer patients and is one of the most common complications of cancer patients and anticancer therapy. Complication of VTE can increase the mortality of cancer patients for 2- to 8-fold. The risk of thromboembolism is associated with the site and pathologic type of primary tumor. The entities with the highest incidence of VTE are pancreatic cancer, ovarian cancer, and malignancies of the central nervous system, followed by gastrointestinal malignancies, bladder cancer, and lung cancer. Clinical presentation of VTE is often nonspecific, most patients with cancer have blood coagulation test abnormalities indicative of up-regulation of the coagulation cascade, increased platelet activation and aggregation, and increased proteolysis. The incidence of venous thromboembolism (VTE) is increased by surgery, chemotherapy, radiotherapy, disease progression, and especially those with risk factors such as immobility for a long period of time, endocrine therapy, and application of indwelling central venous catheters. Diagnostic algorithms utilizing various noninvasive tests have been developed to determine the pretest probability of VTE results of D-dimer assay, doppler ultrasonography and angio-Computed Tommography. The objective of this study is to signal problems that may arise during the diagnostic and therapeutic procedure in patients with cancer and venous thromboembolism.

Share this article